Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
To fully understand what this warning means, the clinical evidence behind it, and who should consider alternatives due to an increased risk of medullary thyroid carcinoma, let's take a closer look
Unlike earlier generation mono-agonists (targeting only GLP-1) or dual-agonists (targeting GLP-1 and GIP), Retatrutide exhibits high affinity for three distinct receptor sites: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor
Prompt evaluation can prevent serious complications and guide appropriate management decisions
Medical Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment
US$ 25.45
US$ 27.44
US$ 28.11
